



## **Aerpio Pharmaceuticals to Announce Third Quarter 2018 Financial Results and Host Conference Call on Wednesday, November 7, 2018**

October 31, 2018

CINCINNATI--(BUSINESS WIRE)--Oct. 31, 2018-- Aerpio Pharmaceuticals, Inc. (NASDAQ:ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, today announced that its third quarter 2018 financial results will be released before the market opens on Wednesday, November 7, 2018. Following the release, the Company will host a live conference call and webcast at 8:30 a.m. EST to discuss the Company's financial results and provide a general business update.

The live webcast and a replay may be accessed by visiting Aerpio's website at <http://ir.aerpio.com/>. Please connect to the Company's website at least 15 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast. Alternatively, please call (877) 216-7943 (U.S.) or (417) 629-5045 (international) to listen to the live conference call. The conference ID number for the live call is 4090026. Please dial in approximately 10 minutes prior to the call. Telephone replay will be available approximately two hours after the call. To access the replay, please call (855) 859-2056 (U.S.) or (404) 537-3406 (international). The conference ID number for the replay is 4090026.

### **About Aerpio Pharmaceuticals**

Aerpio Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing first-in-class compounds that activate Tie2 to treat ocular diseases and complications of diabetes. Tie2 is an important regulator of vascular stability and its down-regulation is found in patients with diabetes. Down-regulation is caused by activation of two inhibitors of Tie2, VE-PTP and Ang-2 due to hypoxia or tissue ischemia. The Company's lead compound, AKB-9778, is a systemically-administered small molecule activator of the Tie2 pathway (via highly selective and potent deactivation of VE-PTP) and is in clinical development for the treatment of non-proliferative diabetic retinopathy. AKB-9778 is also being investigated for its potential utility in treating diabetic nephropathy and an eyedrop formulation is in development as a potential treatment for open-angle glaucoma. For more information, please visit [www.aerpio.com](http://www.aerpio.com).

View source version on businesswire.com: <https://www.businesswire.com/news/home/20181031005216/en/>

Source: Aerpio Pharmaceuticals, Inc.

### **Investors & Media:**

#### **Aerpio Pharmaceuticals, Inc.**

Michael Rogers

Chief Financial Officer

[mrogers@aerpio.com](mailto:mrogers@aerpio.com)

or

#### **Burns McClellan, on behalf of Aerpio Pharmaceuticals, Inc.**

Media:

Nancie Steinberg / Robert Flamm, Ph.D.

[nsteinberg@burnsmc.com](mailto:nsteinberg@burnsmc.com) / [rflamm@burnsmc.com](mailto:rflamm@burnsmc.com)

or

Investors:

Ami Bavishi

[abavishi@burnsmc.com](mailto:abavishi@burnsmc.com)